We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Moves -0.03%: What You Should Know
Read MoreHide Full Article
McKesson (MCK - Free Report) closed at $508 in the latest trading session, marking a -0.03% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.
The prescription drug distributor's shares have seen a decrease of 9.4% over the last month, not keeping up with the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.
Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $7.09, reflecting a 13.8% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $89.57 billion, indicating a 16% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $32.07 per share and revenue of $353.29 billion, which would represent changes of +16.87% and +14.35%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for McKesson. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 1.97% rise in the Zacks Consensus EPS estimate. At present, McKesson boasts a Zacks Rank of #3 (Hold).
With respect to valuation, McKesson is currently being traded at a Forward P/E ratio of 15.85. This expresses a discount compared to the average Forward P/E of 18.4 of its industry.
One should further note that MCK currently holds a PEG ratio of 1.18. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Dental Supplies industry had an average PEG ratio of 1.92 as trading concluded yesterday.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 33% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Moves -0.03%: What You Should Know
McKesson (MCK - Free Report) closed at $508 in the latest trading session, marking a -0.03% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.
The prescription drug distributor's shares have seen a decrease of 9.4% over the last month, not keeping up with the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.
Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $7.09, reflecting a 13.8% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $89.57 billion, indicating a 16% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $32.07 per share and revenue of $353.29 billion, which would represent changes of +16.87% and +14.35%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for McKesson. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 1.97% rise in the Zacks Consensus EPS estimate. At present, McKesson boasts a Zacks Rank of #3 (Hold).
With respect to valuation, McKesson is currently being traded at a Forward P/E ratio of 15.85. This expresses a discount compared to the average Forward P/E of 18.4 of its industry.
One should further note that MCK currently holds a PEG ratio of 1.18. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Dental Supplies industry had an average PEG ratio of 1.92 as trading concluded yesterday.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 33% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.